These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26415374)

  • 61. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.
    Paiva B; Martinez-Lopez J; Vidriales MB; Mateos MV; Montalban MA; Fernandez-Redondo E; Alonso L; Oriol A; Teruel AI; de Paz R; Laraña JG; Bengoechea E; Martin A; Mediavilla JD; Palomera L; de Arriba F; Bladé J; Orfao A; Lahuerta JJ; San Miguel JF
    J Clin Oncol; 2011 Apr; 29(12):1627-33. PubMed ID: 21402611
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.
    Larsen JT; Kumar SK; Dispenzieri A; Kyle RA; Katzmann JA; Rajkumar SV
    Leukemia; 2013 Apr; 27(4):941-6. PubMed ID: 23183428
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests.
    Kubicki T; Dytfeld D; Baszczuk A; Wysocka E; Komarnicki M; Lewandowski K
    Postepy Hig Med Dosw (Online); 2017 Jan; 71(0):40-46. PubMed ID: 28181910
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
    Caillon H; Avet-Loiseau H; Attal M; Moreau P; Decaux O; Dejoie T
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e228-e237. PubMed ID: 30799237
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
    Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
    [No Abstract]   [Full Text] [Related]  

  • 66. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.
    Avivi I; Cohen YC; Joffe E; Benyamini N; Held-Kuznetsov V; Trestman S; Terpos E; Dimopoulos MA; Kastritis E
    Hematol Oncol; 2017 Dec; 35(4):734-740. PubMed ID: 27641057
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.
    Fouquet G; Guidez S; Herbaux C; Van de Wyngaert Z; Bonnet S; Beauvais D; Demarquette H; Adib S; Hivert B; Wemeau M; Berthon C; Terriou L; Coiteux V; Macro M; Decaux O; Facon T; Huglo D; Leleu X
    Clin Cancer Res; 2014 Jun; 20(12):3254-60. PubMed ID: 24714772
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Light-chain removal by plasmapheresis in myeloma-associated renal failure.
    Cserti C; Haspel R; Stowell C; Dzik W
    Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification.
    Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Song JW; Yang WI; Kim JS
    Ann Hematol; 2014 Nov; 93(11):1867-77. PubMed ID: 24947797
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay.
    Sasson SC; McGill K; Wienholt L; Carr A; Brown DA; Kelleher AD; Breit SN; Sewell WA
    Pathology; 2015 Oct; 47(6):564-9. PubMed ID: 26352111
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements.
    Dejoie T; Corre J; Caillon H; Moreau P; Attal M; Loiseau HA
    Leukemia; 2019 Feb; 33(2):313-318. PubMed ID: 30573778
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combined analysis using extended renal reference range of serum free light chain ratio and serum protein electrophoresis improves the diagnostic accuracy of multiple myeloma in renal insufficiency.
    Park JW; Kim YK; Bae EH; Ma SK; Kim SW
    Clin Biochem; 2012 Jul; 45(10-11):740-4. PubMed ID: 22503879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.
    Tovar N; Fernández de Larrea C; Elena M; Cibeira MT; Aróstegui JI; Rosiñol L; Filella X; Yagüe J; Bladé J
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1076-9. PubMed ID: 22430087
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Determination of light chains in serum].
    Hansen CT; Nielsen L; Münster AM; Abildgaard N
    Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies.
    Harding SJ; Mead GP; Bradwell AR; Berard AM
    Clin Chem Lab Med; 2009; 47(3):302-4. PubMed ID: 19676141
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
    Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
    Leleu X; Moreau AS; Weller E; Roccaro AM; Coiteux V; Manning R; Nelson M; Leduc R; Robu D; Dupire S; Hatjiharissi E; Burwick N; Darre S; Hennache B; Treon SP; Facon T; Gertz MA; Ghobrial IM
    Leuk Lymphoma; 2008 Jun; 49(6):1104-7. PubMed ID: 18452095
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.
    Murng SH; Follows L; Whitfield P; Snowden JA; Swallow K; Green K; Sargur R; Egner W
    Clin Exp Immunol; 2013 Feb; 171(2):201-9. PubMed ID: 23286947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.